INTRODUCTION
Lung cancer is a disease of epidemic proportion and is the global cause of cancer death. Only a minority of the patients, about 13 %, will be cured. Palliation is an important part of the lung cancer management due to the late stage of disease at presentation, and the high rate of recurrent and metastatic disease despite previous conventional treatments. Advanced local disease in the central airways has morbid implications [1] [2] [3] [4] [5] . About 30 -40% of all lung cancer patients with locally advanced disease is estimated to suffer from tumor obstruction in whom external radiotherapy is considered the treatment of choice for local control. This category of patients may also be candidates for bronchoscopic treatment. Tumor obstruction causes various pulmonary symptoms: dyspnea, hemoptysis, stridor, and obstructive pneumonia. Ultimately, severe impairment of the gas exchange will lead to respiratory failure. Efforts should be undertaken to improve the quality of life despite the poor prognosis of many patients with advanced stage cancer. Bronchoscopic treatment modalities may provide symptomatic relief, enabling the bronchoscopist to perform tumor debulking [6] . Stent insertion is also possible in cases with extraluminal compression of the airway [7] . These intervention techniques have been shown to be feasible and effective, however, some limitations exist. Experience, skill and knowledge of the anatomy is important to prevent serious complications such as fistula and fatal hemorrhage. It is more difficult to treat tumor extending distal to the segmental bronchi beyond the visibility of the bronchoscopist. The depth of tumor necrosis depends not only on the treatment modality but also on technical performance. The bronchoscopist has to understand the anatomy of the tracheobronchial wall to prevent complications. The tracheobronchial tree is anatomically close to vital organs, especially pulmonary vessels accompanying its branches. This short review will deal with the role of photodynamic therapy in treating patients with locally advanced lung cancer.
TECHNICAL CONSIDERATIONS
Photodynamic therapy (PDT) is the combined use of light and photosensitizers in the presence of oxygen to obtain tissue necrosis. Many reviews have dealt with the basic issues and mechanisms of PDT [8] [9] [10] [11] . In treating lung cancer, patients are given sensitizers systemically by intravenous route [8, 11] . The drugs used for PDT in lung cancer were mainly hematoporphyrin derivative (HpD) and its purified product di-hematoporphyrin ether (Porfimer Sodium, Photofrin IIR, QLT Vancouver Canada), developed by Dougherty [8] . Advised drug doses are 2-5 and 1-2mg/kg respectively. After 24-48h, sufficient sensitizers molecules are accumulated in tumor tissue. No significant drug toxicity has been reported, except for the skin photosensitivity for 6 weeks or more post-injection [12] . The [14] . In vivo studies have shown that the main effect of PDT is acute vascular thrombosis (vascular shut-off), leading to secondary hypoxia and late necrosis [15] . Complex issues remain to be investigated such as the drug pharmacokinetics, the optimal time gate between drug injection and illumination, the sensitizers degradation and depletion of oxygen during illumination procedure [8] [9] [10] [11] 16] . Tumor illumination is easy to perform. Many laser fibers are commercially available to assure homogeneous light distribution. The flexible laser fibers allow easy manipulation for treating tumor extending into the segmental bronchi. The thin laser fiber can be passed through the working channel of a fiberoptic bronchoscope [8, 11] . It is better to illuminate a larger area than the suspicious lesion alone because tumor margins are difficult to delineate. Interstitial illumination are mostly used by sticking the cylindrical diffusers in the intraluminal tumor mass, enabling sideways and more homogeneous illumination along the tracheobronchial wall. Currently, cheaper and more practical PDT FOR ADVANCED LUNG CANCER 247 diode lasers are available as light sources (see Fig. 1 ), which greatly improved the process of illumination compared to the previous bulky, more expensive and difficult to maintain dye laser equipments. The wavelength of light has to correlate with the absorbance characteristics of each sensitizers, to achieve optimal penetration of light photons in tissue [8, 17] . This is why for HpD and DHE, light of 630nm wavelength is used. Another interesting approach is the deliberate use of a specific wavelength, to obtain either superficial or in depth necrosis, to match the tumor thickness preventing overtreatment which may lead to cicatritial fibrosis or perforation [18] . This is particularly important in treating hollow organs to reduce the chance of perforation and extensive tissue scarring. Limiting the damage of normal parenchyma in preserving lung function is the goal of selective treatment in patients whose lung capacity is already reduced by COPD, recurrent tumor, surgical resection and radiotherapy. Light dosimetry remains one of the complex issues in PDT [8, 11, 16] . The ultimate tissue necrosis depends on the activation of sensitizers by light photons in the presence of oxygen. The ideal situation will be the predictability of light dose and light dose fractionation to achieve optimal necrosis in each individual patient at each particular PDT session, taking into account the individual variability of drug molecules distribution. Tumor mass in each individual case is also different in shape and size. Tracheobronchial wall is also non-homogeneous in structure. Photons distribution, absorption, scattering and reflection in tumor tissue containing sensitizers molecules are complex variables. It remains to be seen, whether a feedback monitoring during the illumination process using the real time fluorescence measurement is clinically practical to optimize tumor damage [18] .
Standard protocol of illumination currently applied is in the range of 100-200 J per cm tumor FIGURE A diode laser is now available for light illumination during PDT. After patients have been given photosensitizers, the lesion is illuminated using special laser fiber which transmits the light homogenously around or in the tumor area.
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T.G. SUTEDJA length axis [8, 11] . Bronchoscopic [19, 20] . The late secondary necrosis of PDT makes it unsuitable for patients with severe tracheal obstruction. Immediate airway clearance using techniques such as electrocautery or lasers in combination with mechanical tumor removal are better alternatives.
After tumor illumination during PDT, a clean-up bronchoscopy is essential and may be promptly required for removal of fibrin plugs and necrosis to prevent respiratory failure [8, 11] . Light penetration is also finite. Moreover, one has to consider treatment morbidity in case of palliation. Skin photosensitivity may well be less burdensome for the individual patient, however, there are several alternatives for immediate and non-immediate tumor debulking in case of tumor obstruction in the tracheobronchial tree [6] . [24, 25] .
The various bronchoscopic treatment modalites in this category ofpatients share the similar problem of a negative selection bias [19] . Many patients are suffering from recurrences after previous treatments. They are mostly limited in their pulmonary and cardiac functions because of smoking history, underlying diseases such as COPD, previous surgery and external radiation therapy [3, 6, 19] . So, inadequate performance of intervention techniques can worsen patients' condition if significant residual tumor obstruction in the major airways persists.
PDT illumination, however, is easy to perform. One has only to position the fiber on top of (surface illumination), or in the tumor area (interstitial illumination). The [8, 11, 12] .
PDT may provide an option to reduce intraluminal tumor extent enabling a less extensive surgical resection afterwards [24] . PDT and other bronchoscopic treatment modalities should be part of the treatment strategy within the framework of lung cancer care in combination with surgery, chemotherapy and radiotherapy. This multidisciplinary approach focuses on both palliation and treatment with curative intent [6, 8, 11, 20, 24, 25] . Nevertheless, PDT has been shown to be effective for intraluminal tumor debulking and in achieving long term local control (see Table I ). Skin [11, 20, 24, 25, 34] . The issue is thus more controversial in using PDT for treating patients with locally advanced cancers PDT + RT gave longer remission PDT: better response and lung function improvement Abbreviations: n number of patients in the study; RT radiotherapy.
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Not available 250 T.G. SUTEDJA [6, 7, 19, 20, 35] . The [6] . The choice of treatment is also based on the patients' population referred to each particular institution.
In summary, it remains to be seen whether PDT using new photosensitizers in combination with diode lasers may provide a cost-effective alternative for bronchoscopic treatment in patients with locally advanced lung cancer.
